|
MASH

Explore Therapeutic Areas

Diabetes Icon
Diabetes
Our broad treatment portfolio supports individualized patient care.
Obesity Icon
Obesity
Our treatments are part of a comprehensive approach to weight-loss management.
Growth-Related Disorders Icon
Growth-Related Disorders
Our products help children with a range of growth-related disorders and adults with growth hormone deficiency.
MASH Icon
MASH
Our commitment is to treat and help people living with MASH.
Rare Bleeding Disorders Icon
Rare Bleeding Disorders
Our commitment to patients with hemophilia and rare bleeding disorders is reflected in our broad therapy portfolio.
Rare Renal Disorders Icon
Rare Renal Disorders
Our treatment helps patients with the rare genetic disorder primary hyperoxaluria type 1 (PH1).
Multiple Indications Icon
Multiple Indications
|
|

Explore the Hub

Products
Samples
Patient Savings
Contact

Explore Therapeutic Areas

Diabetes
Diabetes
Obesity
Obesity
Growth-Related Disorders
Growth-Related Disorders
MASH
MASH
Rare Bleeding Disorders
Rare Bleeding Disorders
Rare Renal Disorders
Rare Renal Disorders
Multiple Indications
Multiple Indications
|
|

Explore Current Therapy Area

Disease Education
MASH: A Chronic Disease
Treatment Guidelines
Clinical Guidance
Prescription Savings & Coverage
ICD-10 Codes
Diabetes
Diabetes
Obesity
Obesity
Growth-Related Disorders
Growth-Related Disorders
MASH
MASH
Rare Bleeding Disorders
Rare Bleeding Disorders
Rare Renal Disorders
Rare Renal Disorders
Multiple Indications
Multiple Indications
|

Explore Current Therapy Area

|
Important Safety Information
|

Actor portrayal

Mash Mash

Helping you help patients

MASH is a liver disease linked to metabolic dysfunction that is associated with serious conditions both within the liver and beyond.1,2

MASH=metabolic dysfunction-associated steatohepatitis.

MASH is a progressive form of fatty liver disease that often goes undetected. If left unmanaged, it can worsen over time and lead to potentially life-threatening complications.1,2 However, with timely screening, early detection, and appropriate management, it may be possible to stop or even reverse liver damage caused by MASH.3

MASH=metabolic dysfunction-associated steatohepatitis.

How can we help you today?

Affordability resources for your patients

NovoCare® provides affordability and access support resources to help your patients obtain the medicine that’s right for them. 

Actor portrayal

Actor portrayal

Want to give your patients more support?

NovoCare® provides affordability and access support resources to help your patients obtain the medicine that’s right for them.

What professional education interests you?

MASH: A Chronic Disease
education
Clinical guidance
education
ICD-10 Codes
education

Claim your personalized professional hub

Registering with novoMEDLINK™ allows us to bring the content you need right to your homepage.  

Actor portrayal

References:

  1. Allen AM, Charlton M, Cusi K, et al. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024;136(3):229-245. doi:10.1080/00325481.2024.2325332

  2. Westfall E, Jeske R, Bader AR. Nonalcoholic fatty liver disease: common questions and answers on diagnosis and management. Am Fam Physician. 2020;102(10):603-612.

References:

  1. Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797-1835. doi:10.1097/HEP.000000000000323

  2. Allen AM, Charlton M, Cusi K, et al. Guideline-based management of metabolic dysfunction-associated steatotic liver disease in the primary care setting. Postgrad Med. 2024;136(3):229-245. doi:10.1080/00325481.2024.2325332

  3. Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology clinical practice guideline for the diagnosis and management of nonalcoholic fatty liver disease in primary care and endocrinology clinical settings: co-sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract. 2022;28(5):528-562. doi:10.1016/j.eprac.2022.03.010